GeneDx Holdings Corp
Company Profile
Business description
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
Contact
333 Ludlow Street
North Tower, 6th Floor
StamfordCT06902
USAT: +1 888 729-1206
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
1,300
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,790.20 | 9.20 | -0.10% |
| CAC 40 | 7,981.76 | 5.73 | -0.07% |
| DAX 40 | 24,400.65 | 92.73 | 0.38% |
| Dow JONES (US) | 49,363.88 | 322.24 | -0.65% |
| FTSE 100 | 10,330.55 | 6.80 | 0.07% |
| HKSE | 25,797.85 | 122.67 | 0.48% |
| NASDAQ | 25,870.71 | 220.02 | -0.84% |
| Nikkei 225 | 59,636.23 | 914.36 | -1.51% |
| NZX 50 Index | 12,841.87 | 132.45 | -1.02% |
| S&P 500 | 7,353.61 | 49.44 | -0.67% |
| S&P/ASX 200 | 8,564.30 | 8.80 | -0.10% |
| SSE Composite Index | 4,169.54 | 38.01 | 0.92% |